SYMLIN Improved Diabetes Control In Patients With Type 2 Diabetes On Established Regimens Of Basal Insulin

... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN) today announced positive results from a 16-week studyevaluating the safety and efficacy of adding SYMLIN(R) (pramlintideacetate) to an established regimen of basal insulin glargine (with orwithout oral antidiabetic agents) in patients with type 2 diabetes who havenot progressed to mealtime insulin therapy. [click link for full article] ...